Robert LeBoyer

Yuan Zhi

David Larsen

Bill Sutherland

David Larson

Juan Chee

William Sutherland

- The Oncology Institute (TOI) is the **largest value-based oncology care provider** in the U.S., operating in **five states** with **80 locations**.  **[0001799191_2172480_1]** 
- The company has achieved a **41% revenue CAGR** over the past 18 years  **[0001799191_2172480_4]**  but became unprofitable after going public and expanding.  **[0001799191_2172480_3]** **[0001799191_2172480_4]**  It restructured, removing **$11 million of SG&A** from the business.  **[0001799191_2172480_3]** 
- TOI projects to reach **adjusted EBITDA break-even and profitability in Q4 of this year** (2025).  **[0001799191_2172480_3]** **[0001799191_2172480_4]**  This is driven by **$36 million in incremental revenue** from new value-based contracts (annualized almost $50 million)  **[0001799191_2172480_4]** , **70% year-over-year growth** in its dispensary segment (now **52% of revenue mix** with an **18% margin**)  **[0001799191_2172480_4]** **[0001799191_2172480_5]** , and improved clinical productivity.  **[0001799191_2172480_4]** 
- The company is focused on filling capacity in its existing markets, particularly Florida and Nevada, where higher PMPM (per member per month) rates and benchmark utilization offer significant value.  **[0001799191_2172480_5]** **[0001799191_2172480_7]**  TOI has demonstrated the ability to lower the medical loss ratio (MLR) for new contracts from over **70% to around 50%** within a year.  **[0001799191_2172480_5]**